Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CAPRNASDAQ:IMRNNASDAQ:KTOVNASDAQ:ONCY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$5.15+2.2%$5.58$2.68▼$8.22$162.23M3.99299,000 shs387,928 shsIMRNImmuron$2.49$5.04$1.92▼$28.99$14.19M1.4322,166 shs3,424 shsKTOVPurple Biotech$0.51+4.1%$4.16$2.20▼$14.40$8.06M2.371.18 million shs270,939 shsONCYOncolytics Biotech$1.08+1.9%$1.06$0.88▼$3.39$81.45M1.93369,111 shs302,083 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics+2.18%+1.98%-18.38%+27.16%+30.38%IMRNImmuron0.00%+1.63%-9.80%+34.59%+29.69%KTOVPurple Biotech0.00%+11.21%-17.55%-22.59%-74.11%ONCYOncolytics Biotech+1.89%+4.85%+6.93%-11.48%-14.96%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPRCapricor Therapeutics1.1 of 5 stars3.50.00.00.02.30.80.6IMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech1.1346 of 5 stars3.54.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics3.00Buy$24.00366.02% UpsideIMRNImmuronN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AONCYOncolytics Biotech3.00Buy$4.00270.37% UpsideCurrent Analyst RatingsLatest ONCY, KTOV, CAPR, and IMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/1/2024CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$25.18M6.44N/AN/A$0.73 per share7.05IMRNImmuron$1.22M11.63N/AN/A$2.32 per share1.07KTOVPurple Biotech$1M8.06N/AN/A$5.56 per share0.09ONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$22.29M-$0.87N/A42.92N/A-88.52%-299.67%-45.54%5/9/2024 (Estimated)IMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/AKTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)Latest ONCY, KTOV, CAPR, and IMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/A2/29/2024Q4 2023CAPRCapricor Therapeutics-$0.23-$0.02+$0.21-$0.02$5.80 million$12.09 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A1.631.63IMRNImmuronN/A8.527.79KTOVPurple BiotechN/A2.22N/AONCYOncolytics BiotechN/A9.019.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%IMRNImmuron0.12%KTOVPurple Biotech30.72%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics12.00%IMRNImmuron7.01%KTOVPurple Biotech2.98%ONCYOncolytics Biotech0.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor TherapeuticsN/A31.50 million27.72 millionOptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionableKTOVPurple Biotech915.73 millionN/ANot OptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableONCY, KTOV, CAPR, and IMRN HeadlinesSourceHeadlineOncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meetingfinanznachrichten.de - April 25 at 9:25 AMOncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meetingprnewswire.com - April 25 at 7:00 AMClosing Bell: Oncolytics Bio up on Friday (ONC)theglobeandmail.com - April 21 at 5:51 PMBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Casestheglobeandmail.com - April 13 at 12:42 AMUSA News Group: Biotech Innovations Paving the Way in Breast Cancer Fightfinanznachrichten.de - April 11 at 2:15 PMOncolytics seeking FDA meeting to discuss registration-enabling studymsn.com - April 11 at 2:15 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAprnewswire.com - April 11 at 7:00 AMOncolytics Biotech (NASDAQ:ONCY) Now Covered by Analysts at Raymond Jamesmarketbeat.com - April 4 at 2:58 PMUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer Emergencyfinanznachrichten.de - March 14 at 9:24 AMBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trialsmarkets.businessinsider.com - March 11 at 7:59 AMOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 10 at 10:18 AMBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trialsmarkets.businessinsider.com - March 8 at 8:46 PMOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsfinanznachrichten.de - March 8 at 10:45 AMOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsprnewswire.com - March 7 at 4:01 PMOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANprnewswire.com - March 5 at 7:00 AMOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conferenceprnewswire.com - February 28 at 7:00 AMHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situationfinance.yahoo.com - February 15 at 3:44 PMOncolytics Biotech Incbaystreet.ca - February 15 at 10:44 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsnewsfilecorp.com - February 15 at 8:00 AMOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 1:27 PMOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinance.yahoo.com - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortprnewswire.com - February 14 at 7:00 AMOutlook stock rallies on private placement, FDA study agreementmsn.com - January 23 at 11:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCapricor TherapeuticsNASDAQ:CAPRCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.